Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

When we introduced the Nasdaq IPO Pulse a year ago, we said it suggested that U.S. “IPO activity… should remain in an uptrend” as we headed into 2024. Then, when we introduced the Nasdaq ...

Umm Al Qura for Development and Construction, the developer of the Masar Destination redevelopment initiative in Makkah, ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.